Viewing Study NCT05271318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:58 AM
Ignite Modification Date: 2026-01-22 @ 12:21 AM
Study NCT ID: NCT05271318
Status: RECRUITING
Last Update Posted: 2025-11-03
First Post: 2022-02-04
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Sponsor: TILT Biotherapeutics Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Platinum-refractory Ovarian Carcinoma View
None Platinum-resistant Ovarian Cancer View
None Platinum-Resistant Fallopian Tube Carcinoma View
None Platinum-Resistant Primary Peritoneal Carcinoma View
None Platinum-Refractory Fallopian Tube Carcinoma View
None Platinum-Refractory Primary Peritoneal Carcinoma View
None Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or … View
None Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy … View
None Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Oncolytic virus View
None Virotherapy View
None Immune checkpoint inhibitor View
None Adenovirus View
None TILT-123 View
None Pembrolizumab View
None anti-Programmed Cell Death 1 (anti-PD1) View
None Keytruda View